NEW YORK (GenomeWeb) – T2 Biosystems reported after the close of the market Tuesday that its fourth quarter and full-year 2014 loss increased as it ramped up R&D and invested in clinical trials for its T2Candida Panel and T2Dx instrument.

The Lexington, Mass.-based molecular diagnostics firm reported research and grant revenues for the quarter of $119,000, up from $55,000 in the fourth quarter of 2013. It didn't report any commercial revenues in the quarter or full year.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.